EirGenix Inc. (TPEX:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
61.50
-0.50 (-0.81%)
Apr 24, 2025, 1:30 PM CST
-20.54%
Market Cap 18.94B
Revenue (ttm) 1.01B
Net Income (ttm) -698.34M
Shares Out 305.41M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 192,433
Average Volume 417,857
Open 61.60
Previous Close 62.00
Day's Range 60.70 - 62.00
52-Week Range 52.70 - 100.50
Beta 0.75
RSI 39.90
Earnings Date May 9, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements

News

There is no news available yet.